Return to search

3i Germany puts DM5m (E2.6m) into GenPat77 Pharmacogenetics

The company develops treatments that assist patients dependent on immune therapies.

GenPat77 expects to bring its first commercial drug to market in 2002. The world market for therapeutic treatments is estimated to be $6.9 billion (E7.5 billion).